Punch & Associates Investment Management Inc. Invests $16.23 Million in IQVIA Holdings Inc. $IQV

Punch & Associates Investment Management Inc. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 84,013 shares of the medical research company’s stock, valued at approximately $16,233,000. Punch & Associates Investment Management Inc. owned about 0.05% of IQVIA as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ausdal Financial Partners Inc. bought a new position in shares of IQVIA in the second quarter worth about $263,000. Bank of America Corp DE acquired a new position in IQVIA during the 2nd quarter worth approximately $235,551,000. Magnolia Capital Advisors LLC bought a new position in IQVIA in the 2nd quarter valued at approximately $689,000. Freestone Grove Partners LP bought a new position in IQVIA in the 2nd quarter valued at approximately $38,706,000. Finally, Man Group plc acquired a new stake in IQVIA in the second quarter valued at approximately $57,131,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $261.57 on Thursday. The stock has a market cap of $43.05 billion, a price-to-earnings ratio of 32.45, a P/E/G ratio of 2.22 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $262.51. The company’s fifty day moving average is $218.41 and its 200 day moving average is $188.59. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the business earned $2.81 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. Insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Stifel Nicolaus increased their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Robert W. Baird boosted their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Finally, William Blair raised IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.